

Global Health

Estimate change



TP change



Rating change



Bloomberg	MEDANTA IN
Equity Shares (m)	269
M.Cap.(INRb)/(USDb)	377 / 4.5
52-Week Range (INR)	1514 / 548
1, 6, 12 Rel. Per (%)	0/42/126
12M Avg Val (INR M)	466

Financials & Valuations (INR b)

Y/E MARCH	FY24	FY25E	FY26E
Sales	32.8	35.8	40.3
EBITDA	8.3	9.8	11.3
Adj. PAT	4.8	6.0	7.1
EBIT Margin (%)	19.1	21.9	22.5
Cons. Adj. EPS (INR)	17.8	22.2	26.3
EPS Gr. (%)	46.7	24.9	18.4
BV/Sh. (INR)	108.2	126.5	148.2

Ratios

Net D:E	0.1	0.1	0.0
RoE (%)	17.9	19.0	19.2
RoCE (%)	14.7	16.5	17.5
Payout (%)	17.6	17.6	17.6

Valuations

P/E (x)	78.9	63.2	53.3
EV/EBITDA (x)	46.0	38.6	33.4
EV/Sales (x)	11.6	10.6	9.4
Div. Yield (%)	0.2	0.2	0.3
FCF Yield (%)	0.9	0.6	0.7
EV/Sales (x)	11.6	10.6	9.4

Shareholding pattern (%)

As On	Mar-24	Dec-23	Mar-23
Promoter	33.0	33.1	33.1
DII	10.3	11.2	12.4
FII	12.1	11.4	9.9
Others	44.6	44.4	44.7

FII Includes depository receipts

CMP: INR1460

TP: INR1,620 (+15%)

Buy

Mature hospitals drive YoY earnings growth

Indore back on track/Noida to commence operations in 4QFY25/1QFY26

- Global Health (MEDANTA) missed our earnings estimate for 4QFY24, largely due to subdued performance at Lucknow hospital. This was partly offset by improved occupancy/superior margins in mature hospitals segment.
- We cut our earnings estimates by 7%/6% for FY25/FY26 to factor in a gradual pickup in utilization of beds in developing hospitals, higher opex for bed additions, and reduced operating leverage. We value MEDANTA at 35x 12M forward EV/EBITDA to arrive at a TP of INR1,620.
- MEDANTA has delivered a four-year CAGR of 17%/33%/59% in revenue/EBITDA/PAT over FY20-24. It ended FY24 with 25% YoY earnings growth. MEDANTA continues to add beds at existing sites (Lucknow/Patna/Gurgaon) as well as new sites (Noida/Indore/South Delhi). Earnings growth is largely driven by an increasing number of patients seeking treatment and a moderate increase in realization per patient. This provides robust visibility for earnings growth (22% CAGR over FY24-26). Hence, we maintain BUY.

Increased patients/slight uptick in ARPOB led YoY EBITDA growth

- In 4QFY24, sales grew 15% YoY to INR8.1b. (vs our est. INR8.6b). ARPOB grew by 3.6% YoY to INR63k. In-patient (IPD)/out-patient (OPD) volume grew 10%/11.4% YoY for the quarter.
- EBITDA margin declined by 40bp YoY to 23.6 %. EBITDA grew 13% YoY to INR1.9b (vs our est. INR2.3b).
- Mature hospitals revenue (68% of total revenue) grew 15% YoY to INR6.1b. EBITDA was INR1.5b with 60bp YoY margin expansion to 25.3%.
- Developing hospitals revenue (32% of total revenue) grew 11.9% YoY to INR2.3b. EBITDA was INR623m with 350bp YoY margins contraction to 27.5%.
- PAT grew 26% YoY to INR1.3b.
- During FY24, revenue/EBITDA/PAT grew by 21%/31%/47% YoY to INR32.7b/INR8.3b/INR4.8b.

Highlights from the management commentary

- MEDANTA would incur capex of INR10-12b over the next 2-3 years for the addition of 1,650 beds.
- About 95% of the construction at Noida is completed and the hospital is expected to start operations of 300 beds in 4QFY25/1QFY26.
- Two additional ICUs (56 beds), dialysis extension (23 beds) and chemo daycare (17 beds) would be added in the Patna hospital in 1HFY25.
- 47 ward beds are expected to be added in Lucknow in 1QFY25.
- A mother-and-child care unit started a couple of weeks ago and its effect of same would reflect in 1QFY25 for the Gurugram hospital.
- The green field hospital has got legal clearance in Indore (bed capacity: 300).

Tushar Manudhane - Research Analyst (Tushar.Manudhane@MotilalOswal.com)

Akash Manish Dobhada - Research Analyst (Akash.Dobhada@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Consolidated - Quarterly Earning Model

(INR m)

Y/E March	FY23				FY24				FY23	FY24	FY24E	vs Est
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q			4QE	(%)
Gross Sales	6,172	6,791	6,943	7,071	7,730	8,439	8,365	8,086	27,099	32,751	8,610	-6.1%
YoY Change (%)	27.1	17.6	19.1	14.6	25.2	24.3	20.5	14.4	25.1	21.6	22.4	
Total Expenditure	4,843	5,211	5,316	5,375	5,887	6,255	6,150	6,175	20,746	24,467	6,306	
EBITDA	1,329	1,580	1,627	1,696	1,843	2,185	2,215	1,911	6,352	8,284	2,304	-17.0%
YoY Change (%)	31.2	15.3	18.4	27.6	38.7	38.3	36.1	12.7	40.0	33.7	38.9	
Margins (%)	21.5	23.3	23.4	24.0	23.8	25.9	26.5	23.6	23.4	25.3	26.8	
Depreciation	366	385	414	408	468	485	495	572	1,575	2,020	487	
Interest	185	182	207	205	179	201	177	182	779	739	144	
Other Income	93	155	119	248	215	208	181	274	493	747	286	
PBT before EO expense	871	1,168	1,125	1,331	1,410	1,707	1,724	1,431	4,491	6,271	1,958	-26.9%
Extra-Ord expense/(Income)	0	0	0	0	0	0	0	0	0	0	0	
PBT	871	1,168	1,125	1,331	1,410	1,707	1,724	1,431	4,491	6,271	1,958	-26.9%
Tax	284	311	319	320	390	455	488	157	1,490	1,490	531	
Rate (%)	32.6	26.6	28.4	24.0	27.7	26.6	28.3	11.0	33.2	23.8	27.1	
MI & Profit/Loss of Asso. Cos.	0	0	0	0	0	0	0	0	0	0	0	
Reported PAT	587	857	806	1,011	1,020	1,252	1,235	1,273	3,000	4,781	1,427	-10.8%
Adj PAT	587	857	806	1,011	1,020	1,252	1,235	1,273	3,000	4,781	1,427	-10.8%
YoY Change (%)	40.6	28.0	15.1	72.2	73.8	46.1	53.3	26.0	52.9	46.6	41.2	
Margins (%)	9.5	12.6	11.6	14.3	13.2	14.8	14.8	15.7	11.1	14.6	16.6	

E: MOFSL Estimates, Note: Sum of 4 quarter does not match with full year as the company has restated its number



Highlights from the management commentary

- In FY24, IPD/OPD volume increased by 18%/15% YoY. The company expects the growth in FY25 and subsequent years to be led by an increase in IPD and OPD volume.
- 4QFY24 was subdued for the Lucknow hospital due to weak seasonality, severe winter in Jan'24 and a fewer number of dengue patients during the quarter.
- The hiring of senior clinical talent at the corporate level would increase costs.
- MEDANTA would apply for patient enrolment under the Ayushman Bharat Scheme for utilizing additional beds in Lucknow.
- During FY24, 126 new beds were added (up 4.7% YoY), with 98 in Lucknow and 28 in the Patna hospital.
- During the year, the overall payor mix remained stable YoY.
- PPP patient flow started in Sept'23 and Medanta Patna served over 500 patients during FY24.

Other operational highlights for 4QFY24

- In FY24, ARPOB grew by 4.7% YoY to INR61.9k.
- Mature hospitals revenue (71% of total sales) grew 14.8% YoY to INR23.2b. EBITDA was INR6b for the year with 220bp margins expansion YoY to 25.2%.
- Developing hospitals revenue (29% of total sales) grew 34% YoY to INR9.9b. EBITDA was INR3.2b for the year with margins expansion of 310bp YoY to 32.2%.
- International patients revenue increased by 24% to INR1.9b, driven by increased volume in international patient admissions and higher realizations for FY24.
- Overall in-patient count increased by 15% YoY and out-patient count increased by 18% YoY in FY24.
- OPD Pharmacy business registered revenue growth of 32% YoY to INR1.1b in FY24.

Key exhibits

Exhibit 1: Revenue for hospitals grew 15% YoY in 4QFY24





Exhibit 2: EBITDA margin declined 40bp in 4QFY24



New technologies, bed additions to keep superior prospects intact

Working on multiple levers to increase the number of patients under treatment

- In FY24, revenue from mature hospitals grew 15% YoY to INR23.2b and revenue from developing hospitals grew 34% YoY to INR10b. Revenue growth was driven by higher patient volumes in all facilities, increased occupancy, and technology advancements.
- MEDANTA aims to enhance profitability by augmenting patient volume through the addition of new medical indications, expanding capacity, and leveraging technological advancements.
- The increase in penetration of insurance in the country will continue to provide demand tailwinds for better healthcare services.
- Further, MEDANTA plans to get into the Ayushman Bharat scheme for cardiac sciences, which would further boost occupancy in Lucknow. New capacities, which have come online in Gurugram and Patna hospital, will further drive growth in the medium term.
- We expect an 11% sales CAGR in healthcare services to INR40.5b over FY24-26.

Enhancing efforts to build capabilities and capacities

- MEDANTA has 2,823 beds installed at the end of FY24. It is focusing on growing its capacity to ~3,500-4,000 beds by the end of FY25.
- The company is focusing on increasing its capacity in the north and central India through organic/inorganic opportunities as it wants to deepen its presence in the underpenetrated markets.
- MEDANTA plans to add 47 beds at Lucknow, 56 beds at Patna, and 300 beds at Noida by the end of FY25.
- The company has received approval from the MP High Court to start the construction of its greenfield project at Indore for 300 beds.
- Further, the company has upgraded its capabilities by using advanced AI-powered penumbra lightning technology for treating pulmonary embolism and

other blood clots, exome sequencing, and advanced NICU ambulance and child development center.

- This provides robust runway for growth over the next three to four years.

Strengthening presence in NCR to drive growth in long term

- MEDANTA has entered into a JV with DLF to develop a 400-bed super specialty hospital in Delhi.
- The hospital will offer medical and surgical interventions across more than 20 specialties, including the establishment of a comprehensive cancer health unit.
- After the commercialization of the facility, the bed count would increase to 2,400 in NCR.

Valuation and view

- We cut our earnings estimates by 7%/6% for FY25/FY26 to factor in a gradual pickup in utilization of beds in developing hospitals, higher opex for additional beds, and reduced operating leverage. We value MEDANTA at 35x 12M forward EV/EBITDA to arrive at a TP of INR1,620.
- MEDANTA has delivered a four-year CAGR of 17%/33%/59% in revenue/EBITDA/PAT over FY20-24. Specifically, it ended FY24 with 25% YoY earnings growth. MEDANTA continues to add beds at existing sites (Lucknow/Patna/Gurgaon) as well as new sites (Noida/Indore, South Delhi). Earnings growth is largely driven by an increasing number of patients seeking treatment and a moderate increase in realization per patient. This provides robust visibility for earnings growth (22% CAGR over FY24-26). Hence, we maintain BUY.

Story in charts

Exhibit 3: Expect 18% sales CAGR over FY24-26 in Developing hospitals




Exhibit 4: Expect 11% overall revenue CAGR over FY24-26




Exhibit 5: Expect 270bp margin expansion over FY24-26




Exhibit 6: Expect 22% profit growth over FY24-26




Exhibit 7: Expect return ratio to improve over FY24-26





Exhibit 8: Significant investment in capacity expansion



Financials and valuation

Global Health Ltd. - Income Statement

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Total Income from Operations	14,558	15,004	14,467	21,666	27,099	32,751	35,787	40,317
Change (%)		3.1	-3.6	49.8	25.1	20.9	9.3	12.7
EBITDA	1,857	1,977	1,977	4,539	6,352	8,284	9,841	11,289
Margin (%)	12.8	13.2	13.7	20.9	23.4	25.3	27.5	28.0
Depreciation	1,016	1,150	1,232	1,297	1,575	2,020	2,017	2,214
EBIT	841	827	745	3,242	4,777	6,263	7,825	9,075
Int. and Finance Charges	331	515	672	795	779	739	526	376
Other Income	502	438	314	392	493	747	930	1,048
PBT bef. EO Exp.	1,013	750	387	2,839	4,491	6,271	8,229	9,747
EO Items	-180	-111	-63	-33	0	0	0	0
PBT after EO Exp.	832	639	325	2,806	4,491	6,271	8,229	9,747
Total Tax	319	275	37	844	1,232	1,490	2,256	2,672
Tax Rate (%)	38.4	43.1	11.3	30.1	27.4	23.8	27.4	27.4
Minority Interest	0	0	0	0	0	0	0	0
Reported PAT	513	363	288	1,962	3,259	4,781	5,973	7,075
Adjusted PAT	693	475	351	1,995	3,259	4,781	5,973	7,075
Change (%)		-31.5	-26.1	469.0	63.3	46.7	24.9	18.4
Margin (%)	4.8	3.2	2.4	9.2	12.0	14.6	16.7	17.5

E: MOFSL est.

Global Health Ltd. - Balance Sheet

(INR m)

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Share Capital	491	493	496	506	536	537	537	537
Other equity	12,464	13,002	13,328	15,654	23,746	28,519	33,440	39,268
Net Worth	12,955	13,495	13,823	16,160	24,282	29,056	33,977	39,805
Minority Interest	0	0	0	0	0	0	0	0
Total Loans	8,075	9,289	9,314	11,089	11,220	8,019	6,019	4,019
Deferred Tax Liabilities	286	81	0	0	0	0	0	0
Other Non-Current Liabilities	333	385	426	713	468	399	436	491
Capital Employed	21,649	23,250	23,563	27,963	35,970	37,474	40,432	44,315
Gross Block	11,829	17,488	17,907	20,828	25,087	28,149	33,899	39,899
Less: Accum. Deprn.	3,230	4,198	5,239	6,381	7,956	9,976	11,993	14,207
Net Fixed Assets	8,600	13,290	12,667	14,447	17,131	18,172	21,906	25,692
Goodwill on Consolidation	3,337	3,741	3,489	3,311	3,371	4,187	4,187	4,187
Capital WIP	6,663	3,817	4,638	4,393	3,270	3,875	3,875	3,875
Total Investments	0	0	1	1	1	1	1	1
Other Non-Current Assets	811	1,029	1,124	1,186	1,593	1,718	1,878	2,115
Curr. Assets, Loans & Adv.	4,886	4,786	5,021	8,117	15,795	15,087	14,608	15,214
Inventory	233	385	398	534	604	669	453	510
Account Receivables	1,642	1,492	1,336	1,802	1,942	2,153	2,353	2,651
Cash and Bank Balance	2,665	2,501	2,893	5,118	7,672	4,246	3,767	3,995
Loans and Advances	347	408	394	663	5,577	8,020	8,035	8,059
Curr. Liability & Prov.	2,647	3,412	3,378	3,493	5,190	5,567	6,023	6,770
Account Payables	1,265	1,307	1,316	1,343	1,947	1,868	1,981	2,216
Other Current Liabilities	1,270	1,916	1,785	1,956	2,445	2,757	3,013	3,394
Provisions	112	189	277	193	798	942	1,030	1,160
Net Current Assets	2,239	1,374	1,644	4,625	10,605	9,520	8,585	8,444
Appl. of Funds	21,649	23,250	23,563	27,963	35,970	37,474	40,431	44,314

E: MOFSL Estimates

Financials and valuation

Ratios

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
Basic (INR)								
EPS	2.8	1.9	1.4	7.9	12.1	17.8	22.2	26.3
Cash EPS	6.8	6.5	6.3	13.0	18.0	25.3	29.8	34.6
BV/Share	51.5	53.6	54.8	64.0	90.4	108.2	126.5	148.2
DPS	0.0	0.0	0.0	0.0	0.0	2.7	3.3	4.0
Payout (%)	0.0	0.0	0.0	0.0	0.0	17.6	17.6	17.6
Valuation (x)								
P/E	509.8	744.6	1,010.0	177.8	115.8	78.9	63.2	53.3
Cash P/E	206.8	217.5	223.7	107.8	78.0	55.5	47.2	40.6
P/BV	27.3	26.2	25.6	22.0	15.5	13.0	11.1	9.5
EV/Sales	24.6	24.0	24.9	16.7	14.1	11.6	10.6	9.4
EV/EBITDA	193.2	182.2	182.4	79.5	60.0	46.0	38.6	33.4
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.3
FCF per share	-5.3	-0.5	4.0	1.5	15.2	12.5	8.1	10.4
Return Ratios (%)								
RoE	5.4	3.6	2.6	13.3	16.1	17.9	19.0	19.2
RoCE	7.9	3.3	4.1	10.1	12.2	14.7	16.5	17.5
RoIC	8.4	3.2	4.0	13.1	15.9	15.6	16.2	16.8
Working Capital Ratios								
Asset Turnover (x)	0.7	0.6	0.6	0.8	0.8	0.9	0.9	0.9
Inventory (Days)	6	8	10	8	8	7	6	4
Debtor (Days)	41	36	34	30	26	24	24	24
Creditor (Days)	32	32	33	23	26	21	20	20
Leverage Ratio (x)								
Current Ratio	1.8	1.4	1.5	2.3	3.0	2.7	2.4	2.2
Interest Cover Ratio	2.5	1.6	1.1	4.1	6.1	8.5	14.9	24.1
Net Debt/Equity	0.4	0.5	0.5	0.4	0.1	0.1	0.1	0.0
Net Debt/EBITDA	2.7	3.2	3.0	1.2	-0.3	-0.5	-0.6	-0.7

Global Health Ltd. - Cash Flow Statement

Y/E March	FY19	FY20	FY21	FY22	FY23	FY24	FY25E	FY26E
OP/(Loss) before Tax	833	639	325	2,806	4,492	6,271	8,229	9,747
Depreciation	883	1,150	1,232	1,297	1,499	1,727	2,017	2,214
Interest & Finance Charges	331	515	672	795	779	739	526	376
Direct Taxes Paid	-675	-562	-164	-980	-1,061	-1,775	-2,256	-2,672
(Inc)/Dec in WC	29	21	366	-668	1,028	-531	334	186
CF from Operations	1,400	1,764	2,431	3,250	6,737	6,431	8,850	9,851
Others	255	-13	-13	-137	-292	-311	-930	-1,048
CF from Operating incl EO	1,656	1,751	2,418	3,113	6,445	6,121	7,920	8,803
(Inc)/Dec in FA	-2,986	-1,877	-1,419	-2,731	-2,352	-2,772	-5,750	-6,000
Free Cash Flow	-1,331	-127	998	382	4,093	3,349	2,170	2,803
(Pur)/Sale of Investments								
Others	499	1,007	-972	-1,478	-1,071	-1,636	930	1,048
CF from Investments	-2,488	-871	-2,392	-4,209	-3,423	-4,408	-4,820	-4,952
Inc/(Dec) in Debt	1,643	940	-30	2,152	-275	-4,586	-2,000	-2,000
Interest Paid	-679	-951	-779	-936	-1,054	-553	-526	-376
Others	6	2	2	380	4,785	0	-1,053	-1,247
CF from Fin. Activity	970	-9	-807	1,596	3,456	-5,139	-3,579	-3,623
Inc/Dec of Cash	138	871	-781	500	6,478	-3,426	-479	228
Opening Balance	466	605	1,476	695	1,194	7,672	4,246	3,767
Closing Balance	605	1,476	695	1,194	7,672	4,246	3,767	3,995
Total Cash & Cash Eq	2,665	1,492	1,336	1,802	7,672	4,246	3,767	3,995

Investment in securities market are subject to market risks. Read all the related documents carefully before investing

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.raiani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company

- actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
- received compensation/other benefits from the subject company in the past 12 months
- any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
- Served subject company as its clients during twelve months preceding the date of distribution of the research report.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263;

www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of

Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN : 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.